Evaluation of localized and systemic immune responses in cutaneous leishmaniasis caused by Leishmania tropica: interleukin‐8, monocyte chemotactic protein‐1 and nitric oxide are major regulatory factors

We have established Leishmania tropica as the causative agent of cutaneous leishmaniasis (CL) in the region of India where the disease is endemic. The association between localized and circulating levels of immune‐determinants in CL patients was evaluated. Reverse transcription–polymerase chain reaction analysis revealed up‐regulation of interferon‐γ (IFN‐γ), interleukin (IL)‐1β, IL‐8, tumour necrosis factor‐α (TNF‐α), IL‐10 and IL‐4 in dermal lesions at the pretreatment stage (n = 31) compared with healthy controls (P < 0·001) and a significant down‐regulation after treatment (n = 14, P < 0·05). The results indicated that an unfavourable clinical outcome in CL was not related to an inadequate T helper 1 (Th1) cell response, but rather to impairment in multiple immune functions. Comparative assessment of treatment regimes with rifampicin (RFM) or sodium antimony gluconate (SAG) revealed tissue cytokine levels to be significantly reduced after treatment with RFM (P < 0·005), while no significant decrease was evident in the levels of IFN‐γ, TNF‐α and IL‐10 (P > 0·05) as a result of treatment with SAG. Increased transcripts of monocyte chemoattractant protein‐1 (MCP‐1) (P < 0·001) and inducible nitric oxide synthase (iNOS) (P < 0·05) were evident before treatment in tissue lesions and remained high after treatment. Immunohistochemistry demonstrated strong expression of myeloperoxidase (MPO) and IL‐8, and moderate expression of iNOS in dermal lesions. The expression levels of IL‐8, MCP‐1 and nitric oxide (NO) were high in patient sera before treatment, as determined using cytokine bead array and enzyme‐linked immunosorbent assay (ELISA). At the post‐treatment stage, the serum IL‐8 levels had decreased; however, the levels of MCP‐1 and NO remained high. These data suggest that IL‐8 is an effector immune‐determinant in the progression of CL, whereas NO facilitates the parasite killing by macrophages via MCP‐1‐mediated stimulation.

[1]  R. Kumar,et al.  Correlation of parasitic load with interleukin-4 response in patients with cutaneous leishmaniasis due to Leishmania tropica. , 2009, FEMS immunology and medical microbiology.

[2]  Y. Belkaid,et al.  IL-10 and TGF-β Control the Establishment of Persistent and Transmissible Infections Produced by Leishmania tropica in C57BL/6 Mice , 2008, The Journal of Immunology.

[3]  R. Kumar,et al.  Cutaneous leishmaniasis caused by Leishmania tropica in Bikaner, India: parasite identification and characterization using molecular and immunologic tools. , 2007, The American journal of tropical medicine and hygiene.

[4]  P. Salotra,et al.  Interferon (IFN)–γ, Tumor Necrosis Factor–α, Interleukin-6, and IFN-γ Receptor 1 Are the Major Immunological Determinants Associated with Post–Kala Azar Dermal Leishmaniasis , 2006 .

[5]  F. Pratlong,et al.  Microsatellite analysis reveals genetic structure of Leishmania tropica. , 2006, International Journal of Parasitology.

[6]  Y. Yuhas,et al.  Rifampin Augments Cytokine-Induced Nitric Oxide Production in Human Alveolar Epithelial Cells , 2006, Antimicrobial Agents and Chemotherapy.

[7]  P. Salotra,et al.  Interferon (IFN)-gamma , tumor necrosis factor-alpha , interleukin-6, and IFN-gamma receptor 1 are the major immunological determinants associated with post-kala azar dermal leishmaniasis. , 2006, The Journal of infectious diseases.

[8]  M. Gramiccia,et al.  The current status of zoonotic leishmaniases and approaches to disease control. , 2005, International journal for parasitology.

[9]  V. Mahajan,et al.  Localized cutaneous leishmaniasis due to Leishmania donovani and Leishmania tropica: preliminary findings of the study of 161 new cases from a new endemic focus in himachal pradesh, India. , 2005, The American journal of tropical medicine and hygiene.

[10]  B. Dasgupta,et al.  Infection of Human Mononuclear Phagocytes and Macrophage‐Like THP1 Cells with Leishmania donovani Results in Modulation of Expression of a Subset of Chemokines and a Chemokine Receptor , 2003, Scandinavian journal of immunology.

[11]  A. Koçyiğit,et al.  Antimonial Therapy Induces Circulating Proinflammatory Cytokines in Patients with Cutaneous Leishmaniasis , 2002, Infection and Immunity.

[12]  H. Laufs,et al.  Leishmania Promastigotes Release a Granulocyte Chemotactic Factor and Induce Interleukin-8 Release but Inhibit Gamma Interferon-Inducible Protein 10 Production by Neutrophil Granulocytes , 2002, Infection and Immunity.

[13]  Helmut Laufs,et al.  Inhibition of the Spontaneous Apoptosis of Neutrophil Granulocytes by the Intracellular Parasite Leishmania major1 , 2002, The Journal of Immunology.

[14]  Syamal Roy,et al.  Chemokine-induced leishmanicidal activity in murine macrophages via the generation of nitric oxide. , 2002, The Journal of infectious diseases.

[15]  H. Körner,et al.  Divergent expression of inflammatory dermal chemokines in cutaneous leishmaniasis * , 2002, Parasite immunology.

[16]  B. Foxwell,et al.  Potential of rifamides to inhibit TNF-induced NF-κB activation , 2002 .

[17]  H. Laufs,et al.  Intracellular Survival of Leishmania major in Neutrophil Granulocytes after Uptake in the Absence of Heat-Labile Serum Factors , 2002, Infection and Immunity.

[18]  H. Laufs,et al.  Chemokines, natural killer cells and granulocytes in the early course of Leishmania major infection in mice , 2001, Medical Microbiology and Immunology.

[19]  S. L. Stevens,et al.  IL-1α and TNFα Down-Regulate CRH Receptor-2 mRNA Expression in the Mouse Heart. , 2001, Endocrinology.

[20]  S. Kunkel,et al.  Differential chemokine regulation by Th2 cytokines during human RPE-monocyte coculture. , 2001, Investigative ophthalmology & visual science.

[21]  U. Ritter,et al.  Monocyte chemotactic protein‐1 stimulates the killing of Leishmania major by human monocytes, acts synergistically with IFN‐γ  and is antagonized by IL‐4 , 2000, European journal of immunology.

[22]  Y. Belkaid,et al.  An Immunomodulatory Function for Neutrophils During the Induction of a CD4+ Th2 Response in BALB/c Mice Infected with Leishmania major1 , 2000, The Journal of Immunology.

[23]  Y. Belkaid,et al.  A Natural Model of Leishmania major Infection Reveals a Prolonged “Silent” Phase of Parasite Amplification in the Skin Before the Onset of Lesion Formation and Immunity , 2000, The Journal of Immunology.

[24]  C. Parra-López,et al.  Regulation of protective immunity against Leishmania major in mice. , 1998, Current opinion in immunology.

[25]  K. Dellagi,et al.  Immunologic determinants of disease evolution in localized cutaneous leishmaniasis due to Leishmania major. , 1998, The Journal of infectious diseases.

[26]  F. Liew,et al.  Cutting Edge: Mice Defective in Fas Are Highly Susceptible to Leishmania major Infection Despite Elevated IL-12 Synthesis, Strong Th1 Responses, and Enhanced Nitric Oxide Production , 1998, The Journal of Immunology.

[27]  F. Liew,et al.  Mice defective in Fas are highly susceptible to Leishmania major infection despite elevated IL-12 synthesis, strong Th1 responses, and enhanced nitric oxide production. , 1998, Journal of immunology.

[28]  Jian Li,et al.  Successful therapy of chronic, nonhealing murine cutaneous leishmaniasis with sodium stibogluconate and gamma interferon depends on continued interleukin-12 production , 1997, Infection and immunity.

[29]  I. Xenarios,et al.  IL-4 Rapidly Produced by Vβ4 Vα8 CD4+ T Cells Instructs Th2 Development and Susceptibility to Leishmania major in BALB/c Mice , 1997 .

[30]  I. Xenarios,et al.  IL-4 rapidly produced by V beta 4 V alpha 8 CD4+ T cells instructs Th2 development and susceptibility to Leishmania major in BALB/c mice. , 1997, Immunity.

[31]  L. Ceci,et al.  Evaluation of polymorphonuclear cell and monocyte functions in Leishmania infantum-infected dogs. , 1996, Veterinary immunology and immunopathology.

[32]  P. Melby,et al.  In situ expression of interleukin-10 and interleukin-12 in active human cutaneous leishmaniasis. , 1996, FEMS Immunology & Medical Microbiology.

[33]  I. Becker,et al.  Differential expression of chemokines in patients with localized and diffuse cutaneous American leishmaniasis. , 1996, The Journal of infectious diseases.

[34]  S. Huang,et al.  Mice from a genetically resistant background lacking the interferon gamma receptor are susceptible to infection with Leishmania major but mount a polarized T helper cell 1-type CD4+ T cell response , 1995, The Journal of experimental medicine.

[35]  Chang-Youh Tsai,et al.  Interleukin 8 modulates interleukin-1β, interleukin-6 and tumor necrosis factor-α release from normal human mononuclear cells , 1994 .

[36]  K. Moore,et al.  Intracellular infection by Leishmania donovani inhibits macrophage apoptosis. , 1994, Journal of immunology.

[37]  C. Tsai,et al.  Interleukin 8 modulates interleukin-1 beta, interleukin-6 and tumor necrosis factor-alpha release from normal human mononuclear cells. , 1994, Immunopharmacology.

[38]  R. Strieter,et al.  Interleukin-8 and development of adult respiratory distress syndrome in at-risk patient groups , 1993, The Lancet.

[39]  J. Convit,et al.  Determination of the cytokine profile in American cutaneous leishmaniasis using the polymerase chain reaction , 1993, Clinical and experimental immunology.

[40]  K. Yasumoto,et al.  Tumor necrosis factor alpha and interferon gamma synergistically induce interleukin 8 production in a human gastric cancer cell line through acting concurrently on AP-1 and NF-kB-like binding sites of the interleukin 8 gene. , 1992, The Journal of biological chemistry.

[41]  Erwin G. Van Meir,et al.  Interleukin-8 is produced in neoplastic and infectious diseases of the human central nervous system. , 1992, Cancer research.

[42]  R. Locksley,et al.  Production of interferon gamma, interleukin 2, interleukin 4, and interleukin 10 by CD4+ lymphocytes in vivo during healing and progressive murine leishmaniasis. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[43]  G. Grau,et al.  Serum levels of tumour necrosis factor-alpha and interleukin-1 beta during leprosy reactional states. , 1991, Clinical and experimental immunology.

[44]  F. Liew,et al.  Tumor necrosis factor-alpha synergizes with IFN-gamma in mediating killing of Leishmania major through the induction of nitric oxide. , 1990, Journal of immunology.

[45]  C. Pirmez,et al.  Immunologic responsiveness in American cutaneous leishmaniasis lesions. , 1990, Journal of immunology.

[46]  M. Turner,et al.  Detection of interleukin 8 biological activity in synovial fluids from patients with rheumatoid arthritis and production of interleukin 8 mRNA by isolated synovial cells , 1990, European journal of immunology.

[47]  P. Vassalli,et al.  Tumor‐Necrosis Factor and other Cytokines in Cerebral Malaria: Experimental and Clinical Data , 1989, Immunological reviews.

[48]  M. Meltzer,et al.  Regulation of activated macrophage antimicrobial activities. Identification of lymphokines that cooperate with IFN-gamma for induction of resistance to infection. , 1988, Journal of immunology.

[49]  R. Locksley,et al.  Development of cellular immunity in cutaneous leishmaniasis due to Leishmania tropica. , 1984, The Journal of infectious diseases.